Dear Doctor - Participate in the Survey on probiotics" A new survey has found that the use of probiotics is on the rise, with more people than ever before using these supplements to improve their gut health. The survey, which was conducted by the American Gastroenterological Association, found that nearly 40% of respondents had used probiotics in the past year. This is a significant increase from previous surveys, which found that only 20-25% of people were using probiotics.There are many different reasons why people may be taking probiotics, but the most common reason is to improve digestive health. Probiotics are live bacteria and yeasts that are good for your gut, and they can help to restore the balance of microbes in your gut if it has been disrupted. Probiotics are often taken to help with conditions like irritable bowel syndrome (IBS), diarrhea, and Crohn's disease.If you're thinking about taking probiotics, it's important to talk to your doctor first. Probiotics are generally safe for most people, but there are some potential side effects, and they may not be appropriate for everyone. Participate in Surveys "
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation